Validation of the Patient Health Questionnaire-9 (PHQ-9) for depression screening in adults with epilepsy.

Autor: Rathore JS; Cleveland Clinic Epilepsy Center, Cleveland Clinic Foundation, Cleveland, OH, USA; Department of Neurology and Rehabilitation, Neuropsychiatric Institute, University of Illinois Medical Center at Chicago (UIC), IL, USA. Electronic address: neurocare9@gmail.com., Jehi LE; Cleveland Clinic Epilepsy Center, Cleveland Clinic Foundation, Cleveland, OH, USA; Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; Neurological Institute Center for Outcomes Research and Evaluation, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: JEHIL@ccf.org., Fan Y; Neurological Institute Center for Outcomes Research and Evaluation, Cleveland Clinic Foundation, Cleveland, OH, USA; Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: FanY2@ccf.org., Patel SI; Cleveland Clinic Epilepsy Center, Cleveland Clinic Foundation, Cleveland, OH, USA; MINCEP Epilepsy Care, University of Minnesota Medical Center, Minneapolis, MN, USA. Electronic address: sipatel12@gmail.com., Foldvary-Schaefer N; Cleveland Clinic Epilepsy Center, Cleveland Clinic Foundation, Cleveland, OH, USA; Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: foldvan@ccf.org., Ramirez MJ; Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; Psychology Services, Tampa General Hospital, Tampa, FL, USA. Electronic address: maya.ramirez@gmail.com., Busch RM; Cleveland Clinic Epilepsy Center, Cleveland Clinic Foundation, Cleveland, OH, USA; Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; Department of Psychiatry and Psychology, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: buschr@ccf.org., Obuchowski NA; Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: obuchon@ccf.org., Tesar GE; Cleveland Clinic Epilepsy Center, Cleveland Clinic Foundation, Cleveland, OH, USA; Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; Department of Psychiatry and Psychology, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: TESARG@ccf.org.
Jazyk: angličtina
Zdroj: Epilepsy & behavior : E&B [Epilepsy Behav] 2014 Aug; Vol. 37, pp. 215-20. Date of Electronic Publication: 2014 Jul 26.
DOI: 10.1016/j.yebeh.2014.06.030
Abstrakt: Objective: This study aimed to assess the accuracy and operating characteristics of the Patient Health Questionnaire-9 (PHQ-9) for depression screening in adults with epilepsy.
Methods: Tertiary epilepsy center patients served as the study population, with 237 agreeing to structured interview using the Mini-International Neuropsychiatric Interview (MINI), a "gold standard" instrument developed for rapid diagnosis of neuropsychiatric disorders, including major depressive disorder (MDD); 172 also completed the PHQ-9, and 127 completed both the PHQ-9 and the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) within two days of the MINI. Sensitivity, specificity, positive and negative predictive values, and areas under the ROC curves for each instrument were determined. Cut-points of 10 for the PHQ-9 and 15 for the NDDI-E were used, and ratings at or above the cut-points were considered screen-positive. The PHQ-9 was divided into cognitive/affective (PHQ-9/CA) and somatic (PHQ-9/S) subscales to determine comparative depression screening accuracy.
Results: The calculated areas under the ROC curves for the PHQ-9 (n=172) and the PHQ-9/CA and PHQ-9/S subscales were 0.914, 0.924, and 0.846, respectively, with the PHQ-9 more accurate than the PHQ-9/S (p=0.002) but not different from the PHQ-9/CA (p=0.378). At cut-points of 10 and 15, respectively, the PHQ-9 had higher sensitivity (0.92 vs 0.87) but lower specificity (0.74 vs 0.89) compared with the NDDI-E. The areas under the ROC curves of the PHQ-9 and the NDDI-E showed similar accuracy (n=127; 0.930 vs 0.934; p=0.864).
Significance: The PHQ-9 is an efficient and nonproprietary depression screening instrument with excellent accuracy validated for use in adult patients with epilepsy as well as multiple other medical populations.
(Copyright © 2014 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: